Navigation Links
Amicus Therapeutics Announces Closing of $18.5 Million Registered Direct Offering of Common Stock
Date:3/2/2010

CRANBURY, N.J., March 2 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that it has closed its previously announced registered direct offering of 4.95 million shares of its common stock and warrants to purchase 1.85 million shares of its common stock to a select group of institutional investors. The shares of common stock and warrants were offered in units consisting of one share of common stock and one warrant to purchase 0.375 shares of common stock at a price of $3.74 per unit. The warrants have a term of four years and are exercisable any time on or after the six month anniversary of the date they are issued, at an exercise price of $4.43 per share. The offering resulted in net proceeds of approximately $17.1 million, after deducting placement agent fees and estimated offering expenses. Leerink Swann LLC served as sole placement agent for the offering.

As previously announced, Amicus intends to use the net proceeds from the offering for general corporate purposes and to further advance the development of the Company's lead product candidate, Amigal™(migalastat HCl), including the initiation of the Phase 3 study to support registration in the European Union and the completion of certain activities required for the submission of a license application globally.

The shares and warrants described above were offered by Amicus pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov or by calling Leerink Swann, toll free, at 1-800-808-7525, Ext. 4814.

About Amicus Therapeutics

Amicus Therapeutics is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program is in Phase 3 for the treatment of Fabry disease.  

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the Company's offering of common stock described herein, including but not limited to statements regarding the proposed use of proceeds from the offering and the clinical development of Amigal™ (migalastat HCl) for Fabry disease. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties including the risk that adverse events could cause the cessation or delay of the closing of the proposed offering. In addition, all forward looking statements are subject to other risks and uncertainties detailed in our Annual Report on Form 10-K for the year ended December 31, 2008, as supplemented by our subsequent public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

SOURCE Amicus Therapeutics

Back to top

RELATED LINKS
http://www.amicustherapeutics.com/

'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... 2016  Celsion Corporation (NASDAQ: CLSN ), ... from the first cohort of patients in its ... Study) combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... In the first three patients dosed, GEN-1 plus ...
(Date:4/29/2016)... , April 29, 2016 /PRNewswire/ ... Contamine, Directeur Financier Sanofi, ... santé, publie ses résultats pour le ... du Groupe, Jérôme Contamine, commente les ... et les perspectives pour le reste ...
(Date:4/28/2016)... -- Research and Markets has announced the ... 2016-2020" report to their offering.      ... global plastic surgery products market is expected to grow ... , ,The growing adoption of laser in aesthetics is ... market. Lasers are used to treat a broad range ...
Breaking Medicine Technology:
(Date:5/2/2016)... WACO, Texas (PRWEB) , ... May 02, 2016 , ... ... Corporation will offer an incentive to people who share their fitness journey on ... footwear and premium first aid products, will award a $100 product voucher each week ...
(Date:5/2/2016)... New York, NY (PRWEB) , ... May 02, 2016 , ... ... Highlighting the year’s best in pet gear and toys, leading product review site ... TTPM Pets Paw of Excellence Awards at their Spring Showcase at the Metropolitan ...
(Date:5/2/2016)... Netherlands (PRWEB) , ... May 02, 2016 , ... Further ... honored to announce that the new WHIMZEES Variety Value Boxes were selected from over ... New Product Showcase Award. , WHIMZEES natural dental chews for dogs are a ...
(Date:5/2/2016)... Rafael, CA (PRWEB) , ... May 02, 2016 , ... The 2016 World Ultimate & ... Nike Ultimate Camp at Manhattan College, made the cut. The WUGC is being held in ... National Teams won the gold in the men’s division, another gold in the women’s masters ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... (AAC) event, will be held at the Bellagio Hotel in Las Vegas, NV ... Social Work (NASW) will be co-hosting the event. , This year’s conference will ...
Breaking Medicine News(10 mins):